The albumin in acute stroke (ALIAS) multicenter clinical trial: Safety analysis of part 1 and rationale and design of part 2

Myron Ginsberg, Yuko Y. Palesch, Renee H. Martin, Michael D. Hill, Claudia S. Moy, Bonnie D. Waldman, Sharon D. Yeatts, Diego Tamariz, Karla Ryckborst

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Background and Purpose-Enrollment in the Albumin in Acute Stroke (ALIAS) Trial was suspended in late 2007 due to a safety concern. We present the safety data of that Trial ("Part 1") and the rationale for the design of Part 2. Methods-ALIAS Part 1 was designed to assess whether 25% albumin (ALB) started within 5 hours of stroke onset would confer neuroprotection in subjects with acute ischemic stroke and baseline National Institutes of Health Stroke Scale of ≥6. Exclusion criteria included recent or current congestive heart failure, myocardial infarction, or cardiac surgery. The study comprised 2 cohorts: subjects who received thrombolysis and those who did not, each with 1:1 randomization to ALB or placebo. The primary outcome was the National Institutes of Health Stroke Scale and modified Rankin Scales at 90 days. The intended sample size was 1800. Results-Four hundred thirty-four subjects were enrolled, and 424 were used in the safety analysis (ALB 207, saline 217). There were 36 deaths within the first 30 days in the ALB group and 21 in the saline group. In contrast, death rates after 30 days were similar by treatment. Large strokes were the predominant cause of early death in both groups. In subjects >83 years of age, 90-day death rates were 2.3-fold higher with ALB than with saline (95% CI, 1.04 to 5.12). Similarly, 90-day deaths in subjects receiving excessive fluids were 2.10-fold greater with ALB than with saline (CI, 1.10 to 3.98). Conclusions-The ALIAS Part 2 Trial, which started in early 2009, was modified as follows to enhance safety: upper age limit of 83 years; requirement for normal baseline serum troponin level; restriction of total intravenous fluids in the first 48 hours to ≤4200 mL; mandatory diuretic at 12 to 24 hours; and detailed site retraining. Because of insufficient nonthrombolysed subjects (22%) in Part 1, the 2-cohort design was eliminated. The Data Safety Monitoring Board has reviewed the safety data of Part 2 3 times and has approved continuation of the trial.

Original languageEnglish
Pages (from-to)119-127
Number of pages9
JournalStroke
Volume42
Issue number1
DOIs
StatePublished - Jan 1 2011

Fingerprint

Multicenter Studies
Albumins
Stroke
Clinical Trials
Safety
National Institutes of Health (U.S.)
Clinical Trials Data Monitoring Committees
Troponin
Mortality
Random Allocation
Diuretics
Sample Size
Thoracic Surgery
Cause of Death
Heart Failure
Myocardial Infarction
Placebos
Serum

Keywords

  • Albumin
  • Ischemic stroke
  • Neuroprotectant
  • Randomized controlled trial

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Clinical Neurology
  • Advanced and Specialized Nursing

Cite this

The albumin in acute stroke (ALIAS) multicenter clinical trial : Safety analysis of part 1 and rationale and design of part 2. / Ginsberg, Myron; Palesch, Yuko Y.; Martin, Renee H.; Hill, Michael D.; Moy, Claudia S.; Waldman, Bonnie D.; Yeatts, Sharon D.; Tamariz, Diego; Ryckborst, Karla.

In: Stroke, Vol. 42, No. 1, 01.01.2011, p. 119-127.

Research output: Contribution to journalArticle

Ginsberg, M, Palesch, YY, Martin, RH, Hill, MD, Moy, CS, Waldman, BD, Yeatts, SD, Tamariz, D & Ryckborst, K 2011, 'The albumin in acute stroke (ALIAS) multicenter clinical trial: Safety analysis of part 1 and rationale and design of part 2', Stroke, vol. 42, no. 1, pp. 119-127. https://doi.org/10.1161/STROKEAHA.110.596072
Ginsberg, Myron ; Palesch, Yuko Y. ; Martin, Renee H. ; Hill, Michael D. ; Moy, Claudia S. ; Waldman, Bonnie D. ; Yeatts, Sharon D. ; Tamariz, Diego ; Ryckborst, Karla. / The albumin in acute stroke (ALIAS) multicenter clinical trial : Safety analysis of part 1 and rationale and design of part 2. In: Stroke. 2011 ; Vol. 42, No. 1. pp. 119-127.
@article{2de1c955b3804a74ab6a1aeef632088c,
title = "The albumin in acute stroke (ALIAS) multicenter clinical trial: Safety analysis of part 1 and rationale and design of part 2",
abstract = "Background and Purpose-Enrollment in the Albumin in Acute Stroke (ALIAS) Trial was suspended in late 2007 due to a safety concern. We present the safety data of that Trial ({"}Part 1{"}) and the rationale for the design of Part 2. Methods-ALIAS Part 1 was designed to assess whether 25{\%} albumin (ALB) started within 5 hours of stroke onset would confer neuroprotection in subjects with acute ischemic stroke and baseline National Institutes of Health Stroke Scale of ≥6. Exclusion criteria included recent or current congestive heart failure, myocardial infarction, or cardiac surgery. The study comprised 2 cohorts: subjects who received thrombolysis and those who did not, each with 1:1 randomization to ALB or placebo. The primary outcome was the National Institutes of Health Stroke Scale and modified Rankin Scales at 90 days. The intended sample size was 1800. Results-Four hundred thirty-four subjects were enrolled, and 424 were used in the safety analysis (ALB 207, saline 217). There were 36 deaths within the first 30 days in the ALB group and 21 in the saline group. In contrast, death rates after 30 days were similar by treatment. Large strokes were the predominant cause of early death in both groups. In subjects >83 years of age, 90-day death rates were 2.3-fold higher with ALB than with saline (95{\%} CI, 1.04 to 5.12). Similarly, 90-day deaths in subjects receiving excessive fluids were 2.10-fold greater with ALB than with saline (CI, 1.10 to 3.98). Conclusions-The ALIAS Part 2 Trial, which started in early 2009, was modified as follows to enhance safety: upper age limit of 83 years; requirement for normal baseline serum troponin level; restriction of total intravenous fluids in the first 48 hours to ≤4200 mL; mandatory diuretic at 12 to 24 hours; and detailed site retraining. Because of insufficient nonthrombolysed subjects (22{\%}) in Part 1, the 2-cohort design was eliminated. The Data Safety Monitoring Board has reviewed the safety data of Part 2 3 times and has approved continuation of the trial.",
keywords = "Albumin, Ischemic stroke, Neuroprotectant, Randomized controlled trial",
author = "Myron Ginsberg and Palesch, {Yuko Y.} and Martin, {Renee H.} and Hill, {Michael D.} and Moy, {Claudia S.} and Waldman, {Bonnie D.} and Yeatts, {Sharon D.} and Diego Tamariz and Karla Ryckborst",
year = "2011",
month = "1",
day = "1",
doi = "10.1161/STROKEAHA.110.596072",
language = "English",
volume = "42",
pages = "119--127",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - The albumin in acute stroke (ALIAS) multicenter clinical trial

T2 - Safety analysis of part 1 and rationale and design of part 2

AU - Ginsberg, Myron

AU - Palesch, Yuko Y.

AU - Martin, Renee H.

AU - Hill, Michael D.

AU - Moy, Claudia S.

AU - Waldman, Bonnie D.

AU - Yeatts, Sharon D.

AU - Tamariz, Diego

AU - Ryckborst, Karla

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Background and Purpose-Enrollment in the Albumin in Acute Stroke (ALIAS) Trial was suspended in late 2007 due to a safety concern. We present the safety data of that Trial ("Part 1") and the rationale for the design of Part 2. Methods-ALIAS Part 1 was designed to assess whether 25% albumin (ALB) started within 5 hours of stroke onset would confer neuroprotection in subjects with acute ischemic stroke and baseline National Institutes of Health Stroke Scale of ≥6. Exclusion criteria included recent or current congestive heart failure, myocardial infarction, or cardiac surgery. The study comprised 2 cohorts: subjects who received thrombolysis and those who did not, each with 1:1 randomization to ALB or placebo. The primary outcome was the National Institutes of Health Stroke Scale and modified Rankin Scales at 90 days. The intended sample size was 1800. Results-Four hundred thirty-four subjects were enrolled, and 424 were used in the safety analysis (ALB 207, saline 217). There were 36 deaths within the first 30 days in the ALB group and 21 in the saline group. In contrast, death rates after 30 days were similar by treatment. Large strokes were the predominant cause of early death in both groups. In subjects >83 years of age, 90-day death rates were 2.3-fold higher with ALB than with saline (95% CI, 1.04 to 5.12). Similarly, 90-day deaths in subjects receiving excessive fluids were 2.10-fold greater with ALB than with saline (CI, 1.10 to 3.98). Conclusions-The ALIAS Part 2 Trial, which started in early 2009, was modified as follows to enhance safety: upper age limit of 83 years; requirement for normal baseline serum troponin level; restriction of total intravenous fluids in the first 48 hours to ≤4200 mL; mandatory diuretic at 12 to 24 hours; and detailed site retraining. Because of insufficient nonthrombolysed subjects (22%) in Part 1, the 2-cohort design was eliminated. The Data Safety Monitoring Board has reviewed the safety data of Part 2 3 times and has approved continuation of the trial.

AB - Background and Purpose-Enrollment in the Albumin in Acute Stroke (ALIAS) Trial was suspended in late 2007 due to a safety concern. We present the safety data of that Trial ("Part 1") and the rationale for the design of Part 2. Methods-ALIAS Part 1 was designed to assess whether 25% albumin (ALB) started within 5 hours of stroke onset would confer neuroprotection in subjects with acute ischemic stroke and baseline National Institutes of Health Stroke Scale of ≥6. Exclusion criteria included recent or current congestive heart failure, myocardial infarction, or cardiac surgery. The study comprised 2 cohorts: subjects who received thrombolysis and those who did not, each with 1:1 randomization to ALB or placebo. The primary outcome was the National Institutes of Health Stroke Scale and modified Rankin Scales at 90 days. The intended sample size was 1800. Results-Four hundred thirty-four subjects were enrolled, and 424 were used in the safety analysis (ALB 207, saline 217). There were 36 deaths within the first 30 days in the ALB group and 21 in the saline group. In contrast, death rates after 30 days were similar by treatment. Large strokes were the predominant cause of early death in both groups. In subjects >83 years of age, 90-day death rates were 2.3-fold higher with ALB than with saline (95% CI, 1.04 to 5.12). Similarly, 90-day deaths in subjects receiving excessive fluids were 2.10-fold greater with ALB than with saline (CI, 1.10 to 3.98). Conclusions-The ALIAS Part 2 Trial, which started in early 2009, was modified as follows to enhance safety: upper age limit of 83 years; requirement for normal baseline serum troponin level; restriction of total intravenous fluids in the first 48 hours to ≤4200 mL; mandatory diuretic at 12 to 24 hours; and detailed site retraining. Because of insufficient nonthrombolysed subjects (22%) in Part 1, the 2-cohort design was eliminated. The Data Safety Monitoring Board has reviewed the safety data of Part 2 3 times and has approved continuation of the trial.

KW - Albumin

KW - Ischemic stroke

KW - Neuroprotectant

KW - Randomized controlled trial

UR - http://www.scopus.com/inward/record.url?scp=79451470799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79451470799&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.110.596072

DO - 10.1161/STROKEAHA.110.596072

M3 - Article

C2 - 21164127

AN - SCOPUS:79451470799

VL - 42

SP - 119

EP - 127

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 1

ER -